Don't Miss
- In Israel, Widespread Vaccination Slashes Severe COVID Cases in Older Patients
- Mental Health ‘Epidemic’ Threatens Communities of Color Amid COVID-19
- Expert Panel Set to Consider Approval of J&J COVID Vaccine
- Health Highlights: Feb. 26, 2021
- Pandemic Is Hitting Hospitals Hard, Including Their Bottom Line
- Common Antidepressants Won’t Raise Risk for Bleeding Strokes: Study
- Hair Salon Talk Can Spread COVID, But Face Shields Cut the Danger
- Menthols Lured 10 Million Americans to Smoking Since 1980: Study
- As Climate Change Lengthens Allergy Season, Pollen Travels Farther
- Masks Vital to Stopping COVID at Gyms, Studies Show
Xtoro Approved for Swimmer’s Ear
By ariannawmd on December 18, 2014

Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer’s ear, clinically known as acute otitis externa.
The infection of the outer ear and ear canal, most often caused by ear canal bacteria, has typical symptoms including pain, swelling, redness and discharge, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in a clinical study of more than 1,200 people, aged 6 months to 85 years. The most common side effects were ear itching and nausea.
Xtoro is produced by Alcon Laboratories, based in Fort Worth, Texas.
More information
The FDA has more about this approval.
Source: HealthDay